Atopic Dermatitis
14
Companies
20
Drug Programs
1
Phase 3
0
Upcoming PDUFAs
Regeneron Pharmaceuticals, Inc.
Dupixent
Eli Lilly and Company
Lebrikizumab
Aclaris Therapeutics, Inc.
ATI-2138
Johnson & Johnson
Experimental Product 1% Colloidal Oatmeal Balm
Forte Biosciences, Inc.
FB-401
VYNE Therapeutics Inc.
FMX114
Aclaris Therapeutics, Inc.
ATI-502
AnaptysBio, Inc.
Placebo
Pfizer
Tilrekimig
Galderma Group AG/ADR
CD5024 0.3% cream
Johnson & Johnson
Experimental Product Colloidal Oatmeal Balm
Kymera Therapeutics, Inc.
KT-621
Aclaris Therapeutics, Inc.
ATI-045
Aclaris Therapeutics, Inc.
ATI-1777
Aclaris Therapeutics, Inc.
ATI-1777 2.0% w/w
Incyte Corporation
Ruxolitinib 0.15% Cream QD
Sanofi
amlitelimab
Myriad Genetics
AdvanceAD-Tx™
Sanofi
OX40L antibody
Aethlon Medical
NOR-101
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | Dupixent | Approved | — | — | — |
| LLY Eli Lilly and Company | Lebrikizumab | Phase 3 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-2138 | Phase 2 | — | — | — |
| JNJ Johnson & Johnson | Experimental Product 1% Colloidal Oatmeal Balm | Phase 2 | — | — | — |
| FBRX Forte Biosciences, Inc. | FB-401 | Phase 2 | — | — | — |
| VYNE VYNE Therapeutics Inc. | FMX114 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-502 | Phase 2 | — | — | — |
| ANAB AnaptysBio, Inc. | Placebo | Phase 2 | — | — | — |
| PFE Pfizer | Tilrekimig | Phase 2 | — | — | — |
| GALDY Galderma Group AG/ADR | CD5024 0.3% cream | Phase 2 | — | — | — |
| JNJ Johnson & Johnson | Experimental Product Colloidal Oatmeal Balm | Phase 2 | — | — | — |
| KYMR Kymera Therapeutics, Inc. | KT-621 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-045 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-1777 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-1777 2.0% w/w | Phase 2 | — | — | — |
| INCY Incyte Corporation | Ruxolitinib 0.15% Cream QD | Phase 2 | — | — | — |
| SNY Sanofi | amlitelimab | — | — | — | — |
| MOLN Myriad Genetics | AdvanceAD-Tx™ | — | — | — | — |
| SNY Sanofi | OX40L antibody | — | — | — | — |
| MDCE Aethlon Medical | NOR-101 | — | — | — | — |
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.